Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Waltraud C. Schrottmaier et al, adding:
”Elevated Levels of Apolipoprotein C3 Impair Platelet Function and Reduce Thrombosis
ApoC3, a known cardiovascular risk factor, paradoxically acts as a lipoprotein-derived inhibitor of platelet aggregation and thrombosis by modulating AKT and VASP signaling and disrupting actin cytoskeleton remodeling, potentially counterbalancing its proatherogenic effects in hyperlipidemia.”
Title: Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Authors: Waltraud C. Schrottmaier, Julia B. Kral-Pointner, Marion Mussbacher, Manuel Salzmann, Bernhard Hochreiter, Anita Pirabe, Theresa Reiter, Sigrun Badrnya, Johannes A. Schmid, Ivo Volf, Alice Assinger
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian